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Abstract: 
Background: Obstructive sleep apnoea (OSA) is associated with increased nitrosative stress, 
endothelial dysfunction, and peripheral neuropathy in patients with type 2 diabetes. We 
hypothesized that OSA is associated with Poly ADP ribose polymerase (PARP) activation, lower intra 
epidermal nerve fibre density (IENFD), and diabetic foot ulceration (DFU). 
Methods: A cross-sectional study of adults with type 2 diabetes recruited from a secondary care 
hospital in the UK. OSA was assessed by multi-channel home-based cardio-respiratory device (Alice 
PDX, Philips Respironics). DPN was assessed using the Michigan Neuropathy Screening Instrument 
(MNSI). IENFD and % PAR stained nuclei were assessed using immunohistochemistry staining on skin 
biopsies. DFU was assessed based on MNSI.   
Results: Skin biopsies and DFU data were available from 52 and 234 patients respectively.  OSA was 
associated with lower IENFD (12.75±1.93 vs. 10.55±1.62 vs. 9.42±1.16 fibres/mm of epidermis for no 
OSA, mild OSA and moderate to severe OSA respectively, p<0.001). Following adjustment, mild (B=-
2.19, p=0.002) and moderate to severe OSA (B=-3.45, p<0.001) were independently associated with 
IENFD. The apnoea hypopnea index (AHI) was associated with IENFD following adjustment (B=-2.45, 
p<0.001). AHI was associated with percentage of PAR stained nuclei following adjustment (B=13.67, 
p=0.025). DFU prevalence was greater in patients with OSA (7.1% vs. 28.1% vs. 26.2% for patients 
with no OSA, mild OSA and moderate to severe OSA respectively, p=0.001). Following adjustment, 
OSA was associated with DFU (OR 3.34, 95%CI 1.19-9.38, p=0.022).  
Conclusions: OSA is associated with lower IENFD, PARP activation and DFU in patients with Type 2 
diabetes. Our finding suggest that OSA is associated with small fiber neuropathy. PARP activation is a 
potential mechanisms linking OSA to DPN and endothelial dysfunction in patients with Type 2 
diabetes. Whether OSA treatment will have a favorable impact on these parameters and DFU 
requires interventional studies.  
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Introduction 
Obstructive sleep apnoea (OSA) is very common in patients with Type 2 diabetes and is 
characterized by recurrent episodes of upper airway obstruction associated with recurrent oxygen 
desaturations, cyclical changes in blood pressure (BP), heart rate and intrathoracic pressure, as well 
as recurrent arousals from sleep and changes in sleep architecture (Tahrani et al., 2013b). 
We have previously shown that OSA was associated with foot insensitivity (based on 10g 
monofilament test) and diabetic peripheral neuropathy (DPN)(based on the Michigan Neuropathy 
Screening Instrument MNSI) (Tahrani et al., 2012a). These assessments are largely based on large 
fiber neuropathy; while the relationship between OSA and small fiber neuropathy is unknown. Intra 
epidermal nerve fiber density (IENFD) is considered an accurate and reproducible measure of early 
diabetic neuropathy and the “gold standard” for small fiber neuropathy (England et al., 2009;Lauria 
et al., 2010;Malik et al., 2011). Hence we hypothesized that OSA was associated with lower IENFD in 
patients with Type 2 diabetes. 
We have also shown previously that OSA was associated with impaired cutaneous microvascular 
function (assessed by Laser Speckle Contrast Imaging technique) and impaired responses to nitric 
oxide(Tahrani et al., 2012a). OSA was associated with increased nitrosative stress and oxidative 
stress in patients with Type 2 diabetes which might have contributed to the associations between 
OSA and impaired microvascular function and DPN(Tahrani et al., 2012a). Hyperglycemia-induced 
nitrosative  and oxidative stress play an important role in the development of vascular disease in 
patients with diabetes, via the activation of Poly ADP ribose polymerase (PARP), the inhibition of 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and the activation of several pathways (such 
as the polyol pathway and advanced-glycation end product (AGE)) resulting in inflammation, 
endothelial dysfunction and microvascular disease(Brownlee, 2005;Tahrani et al., 2010). Hence, we 
hypothesized that OSA is associated with PARP activation in patients with Type 2 diabetes which can 
mediate the relationship between OSA and nitrosative stress and endothelial dysfunction, which we 
described previously (Tahrani et al., 2012a). 
PARP activation and oxidative stress have also been shown to play an important role in the 
pathogenesis of diabetic foot ulceration (DFU) (Tahrani et al., 2012b). Based on the association 
between OSA and DPN, abnormal 10g monofilament, oxidative and nitrosative stress and possibly 
PARP activation, we hypothesized that OSA is associated with DFU in patients with Type 2 diabetes. 
Hence the primary aim of this study is to examine the relationship between OSA and IENFD and 
PARP activation in the skin of patients with Type 2 diabetes. A secondary aim is to explore whether 
there is a link between OSA and DFU in this study population. 
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Methods: 
We conducted an observational cross-sectional study in adults with Type 2 diabetes, the results of  
which have been published previously (Tahrani et al., 2012a). Patients with respiratory disease 
(including pre-diagnosed OSA), end-stage renal disease or non-diabetic neuropathy (<1%) were 
excluded. Patients were recruited opportunistically from the out-patient diabetes departments of a 
UK hospital. Patients were approached in the waiting area before they have seen the clinicians and 
without any prior knowledge of their medical condition. We avoided any reference to snoring during 
the recruitment process.  Consent was obtained and ethnicity self-determined in accordance with 
the UK decennial census by the study participants. The project was approved by the Warwickshire 
Research Ethics Committee (REC number 08/H1211/145) and all patients were consented 
accordingly. 
DPN was assessed using the Michigan Neuropathy Screening Instrument (MNSI), a validated, 2-
component tool designed to facilitate the diagnosis of DPN, which has been widely used 
(1988;1999;Boyraz and Saracoglu, 2010;Feldman et al., 1994a;Martin et al., 2006;Pambianco et al., 
2011).The questionnaire component (MNSIq) comprises 15 questions seeking to characterize 
sensory disturbance, but also peripheral vascular disease and general asthenia (Feldman et al., 
1994b). The examination component (MNSIe) comprises a limited foot inspection to identify 
deformity, skin abnormalities and ulceration, coupled with an assessment of vibratory perception at 
the great toe (measured using a 128 Hz tuning fork) and ankle tendon reflexes. DPN was diagnosed if 
the MNSI examination score was >2 and/or MNSI questionnaire score was ≥ 7 (Martin et al., 
2006;Pambianco et al., 2011). Foot insensitivity to a 10-g monofilament (applied to 10 foot 
locations) was defined as < eight correct responses (Pambianco et al., 2011). 
OSA was assessed by a single overnight home-based cardio-respiratory sleep study using a portable 
multi-channel device (Alice PDX, Philips Respironics) and scored in accordance with the American 
Academy of Sleep Medicine guidelines (Iber C et al., 2007).  An apnoea hypopnea index (AHI) ≥ 5 
events/hour was consistent with the diagnosis of OSA (Epstein et al., 2009). Sleep studies with <4 
hours of adequate recordings were repeated and excluded if the quality remained poor. All sleep 
studies were scored independently by two researchers. 
All patients of the original study were approached to provide skin samples to assess IENFD and %PAR 
stained nuclei, and skin biopsies were performed on patients who consented. Skin biopsies were 
obtained from the mid-thigh level under local anesthetic and using aseptic techniques. 
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IENFD was assessed as we described previously (Tahrani et al., 2012b) and recommended by others 
(Lauria et al., 2010). Four randomly selected 50 µm sections were immunohistochemically stained 
using a free floating protocol with rabbit anti-human polyclonal PGP9.5 antibody (Biogenesis 
1:1200). Individual ENFs were counted as they passed through the basement membrane. Negative 
controls comprised replacing the PG 9.5 antibody with rabbit immunoglobulin.  Epidermal nerve 
counts were expressed as the number of fibers per millimeter of epidermis. 
PARP activity was measured using immunohistochemical method that quantifies the accumulation of 
PAR, the product of the PARP activation (Obrosova et al., 2004;Szabó et al., 2002). PAR was assessed 
as we described previously (Tahrani et al., 2012b). Paraffin sections (4µm) were dewaxed and 
endogenous peroxidases removed and blocked. After antigen retrieval, mouse monoclonal anti PAR 
antibody (1:400) (Enzo Life Sciences, Exeter, UK) was applied and then washed. Sections were 
incubated with ImPRESS universal reagent (Vector Laboratories). Immunoreactivity was revealed 
using diaminobenzidine (Vector Laboratories) and sections counterstained with haematoxylin. The 
number of stained and unstained endothelial nuclei were counted in ten fields from each section, 
using 400X magnification resulting in 300-400 nuclei being assessed. The results are expressed as % 
PAR stained nuclei (Szabó et al., 2002). 
Foot ulceration was assessed in the whole of the original study population (i.e. not only those who 
consented for skin biopsies) during foot exam, and based on question 8 of the MNSIq “Have you 
ever had an open sore on your foot?” 
All Laboratory, sleep and clinical assessments were blinded.  
Data analysis was performed using SPSS 22.0 software (SPSS Inc, Chicago, USA). Data are presented 
as mean (SD). Differences between independent groups were assessed by analysis of variance 
(ANOVA).  Categorical variables were compared using the Chi-squared test or Fisher’s exact test. 
Correlations between continuous variables were performed using the Pearson or Spearman tests. 
Multiple linear regression (forced entry method) was used to assess independent associations of 
continuous outcomes and independent variables (for example the relationship between IENFD and 
OSA and AHI). Non-normally distributed variables were log transformed when used in the linear 
regression models (AHI was transformed to log (AHI+1), 1 was added as some AHI values were 0). 
Dummy variables were used in linear regression models if the independent variable was categorical 
with more than 2 categories (such as OSA status: no OSA, mild OSA and moderate to severe OSA). In 
multiple linear regression, residual distribution was examined and multicollinearity was assessed 
using correlations, the tolerance, variance inflation factor (VIF) and condition index. To assess 
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whether OSA status or OSA severity are associated with DFU, multiple logistic regression (forced 
entry method) was used where DFU was the dependent variable and OSA and other variables were 
the independent variables. Variables included in the regression models were based on known 
outcome-related risk factors.   A p value < 0.05 was considered significant. 
Results 
Data regarding DFU was available in the whole population of the original study (n=234), of which 52 
patients agreed to have skin biopsies (Figure 1). PAR staining was available for all 52 patients while 
IENFD results were available for 48 patients. Of the 52 patients who had skin biopsies, the 
prevalence of OSA was 83% (43/52), with 24 (46%) mild OSA and 19 (37% ) moderate to severe OSA. 
Of the original study population the prevalence of no OSA, mild OSA and moderate-severe OSA was 
36%  (83/234), 39%  (90/234) and 26% (61/234). 
 The skin biopsy study population characteristics in accordance with OSA severity are summarized in 
Table 1. There were no statistically significant difference between patients with and without OSA 
with regards to important characteristics including age, diabetes duration, lipids profile, HbA1c, 
blood pressure (BP) and body mass index (BMI).  There was a non-significant stepwise reduction in 
estimated glomerular filtration rate (eGFR) between patients with no OSA and those with mild and 
moderate to severe OSA as reported previously (Tahrani et al., 2013a). Patients with OSA had higher 
MNSIe scores indicating more DPN in patients with OSA as previously reported (Tahrani et al., 
2012a). There were more men and more White Europeans in patients with OSA, but these 
differences were not statistically significant. There were no differences in alcohol intake or smoking 
between groups. Insulin prescription was similar across groups and a high proportion of all groups 
were prescribed BP lowering and lipid lowering treatments.  
OSA and IENFD 
Results of IENFD were available in 48 patients (4 patients did not have enough tissue left to perform 
PAR immunostaining but not IENFD) , 9 patients with no OSA, 22 with mild OSA and 17 with 
moderate to severe OSA.  
In ANOVA, there was a significant reduction in IENFD across groups (12.75±1.93 vs. 10.55±1.62 vs. 
9.42±1.16 fibers/mm of epidermis for no OSA, mild OSA and moderate to severe OSA respectively, 
p<0.001) (Figure 2). IENFD correlated negatively with the AHI (r=-0.51, p<0.001) and ODI (r=-0.33, 
p=0.02). There were no associations between IENFD and time spent with oxygen saturation < 90% 
(r=0.08, p=0.57) or nadir nocturnal oxygen saturation (r=0.02, p=0.9). 
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Using multiple linear regression, where IENFD was the dependent variable and OSA, age, gender, 
ethnicity, diabetes duration, HbA1c and BMI were the independent variables (R2=0.43); mild OSA 
(B=-2.19, p=0.002) and moderate to severe OSA (B=-3.45, p<0.001) were associated with IENFD. 
Replacing OSA with log (AHI+1) in the model showed that IENFD was associated with log (AHI+1) 
(R2=0.37) (B=-2.45, p<0.001). The regression coefficient suggests that lower AHI values were 
associated with higher IENFD. Similar results were found when log (ODI+1) was used in the model 
instead of log (AHI+1) (R2=0.29) (B=-2.10, p=0.004). 
OSA and PAR 
There was a statistically non-significant trend of increasing %PAR stained nuclei with worsening OSA 
(55.17±20.91 vs. 58.89±17.24 vs. 66.84±15.73 for patients with no OSA, mild OSA and moderate to 
severe OSA respectively, p=0.18) (Figure 3). Log (AHI+1) correlated with %PAR stained nuclei (r=0.29, 
p=0.039) but there was no significant correlation between log (ODI+1) and %PAR stained nuclei 
(r=0.23, p=0.097). 
Using the same multiple linear regression model described above but replacing IENFD with %PAR 
stained nuclei as the dependent variable (R2=0.20) showed no relationship between %PAR stained 
nuclei and mild OSA (B=5.86, p=0.4,) or moderate to severe OSA (B=14.33, p=0.068). However, there 
was an association between log (AHI+1) and %PAR stained nuclei when log (AHI+1) was used in the 
model instead of OSA (B=13.67, p=0.025). The regression coefficient suggests that higher AHI was 
associated with higher %PAR stained nuclei.  
OSA and DFU 
The baseline characteristics of the original study (n=234) in relation to OSA status are summarized in 
Table 2 and were published previously(Tahrani et al., 2012a). Patients with OSA were older, heavier 
and had longer diabetes duration and higher prevalence of peripheral vascular disease (PVD, based 
on the patients electronic records). OSA was also more common in men and in White Europeans. 
OSA patients were prescribed more insulin and anti-hypertensive medication compared to those 
without OSA. 
The prevalence of DFU on clinical examination was 3.4% (n=8). There was a stepwise increase in the 
prevalence of DFU in patients with no OSA vs. mild OSA vs. moderate to severe OSA (0% (0) vs. 2.2% 
(2) vs. 10% (6), p=0.004).Due to the small number of patients with DFU on clinical examination, we 
could not perform logistic regression to assess independent associations. 
Based on question 8 of the MNSIq, 47/234 (20.1%) patients had past history of DFU. The prevalence 
of a past history of DFU was significantly greater in patients with OSA (7.1% (6/84) vs. 28.1% (25/89) 
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vs. 26.2% (16/61) for patients with no OSA, mild OSA and moderate to severe OSA respectively, 
X2=13.75, p=0.001). 
Using the presence of DFU past history (based on the MNSIq) as the dependent variable and OSA, 
age, gender, ethnicity, diabetes duration, Presence of PVD, BMI, HbA1c, and insulin treatment 
(Nagelkerke R2= 0.25) showed that OSA was associated with past history of DFU (OR 3.34, 95%CI 
1.19-9.38, p=0.022). Using the same model but replacing OSA (binary yes/no category) with OSA 
severity showed that mild OSA was associated with past history of DFU (OR 3.69, 95%CI 1.28-10.63, 
p=0.016) and there was a statistically non-significant association with moderate to severe OSA (OR 
2.88, 95%CI 0.87-9.54, p=0.084). 
Conclusions 
We have shown that OSA and AHI are associated with lower IENFD, AHI is associated with PARP 
activation and OSA is associated with DFU in patients with Type 2 diabetes. To the best of our 
knowledge, this is the first report to describe the relationships between OSA and IENFD, PARP 
activation and DFU in patients with Type 2 diabetes. 
IENFD has been shown to have high sensitivity and specificity to diagnose DPN, particularly small 
fiber neuropathy (England et al., 2009;Lauria et al., 2010;Malik et al., 2011). Intra- and inter-
observer variability for the assessment of IENFD demonstrates good agreement (Malik et al., 2011). 
IENFD was found to correlate inversely with thermal thresholds and pain severity(Malik et al., 2011). 
The lower IENFD in patients with OSA and Type 2 diabetes vs. patients with Type 2 diabetes only 
suggest that OSA is associated with small fiber neuropathy in patients with Type 2 diabetes which 
complements our previous finding that OSA was associated with clinically evident DPN and foot 
insensitivity suggesting that OSA in patients with Type 2 diabetes is associated with both small and 
large fibers neuropathy. Even mild OSA was independently associated with lower IENFD, which 
might reflect the relatively long diabetes duration in these patients that could amplify the impact of 
mild OSA in vulnerable tissues. Thus, assessing patients with shorter diabetes duration might yield 
different results. This finding was also similar to our previous study showing that mild OSA was 
independently associated with clinically evident DPN(Tahrani et al., 2012a). Obesity also is an 
established risk factor for DPN and SDB (Tahrani et al., 2013b;Tesfaye et al., 2005); in addition IENFD 
has been shown to correlate negatively with BMI (Smith and Singleton, 2013). However, in this study 
there were no significant differences in BMI between groups and the associations between IENFD 
and SDB remained significant despite adjustment for BMI in the multivariable analysis. 
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PARP activation, secondary to oxidative stress-induced DNA damage, has been shown to play an 
important role in the pathogenesis of DPN and endothelial dysfunction in patients with diabetes 
(Obrosova et al., 2004;Szabó et al., 2002). In our study, PARP activation was independently 
associated with higher AHI; this is likely to be due to DNA damage secondary to oxidative stress in 
patients with OSA and type 2 diabetes. We have shown previously that OSA in patients with type 2 
diabetes was associated with increased oxidative and nitrosative stress (Tahrani et al., 2012a). In 
addition, PARP activation offers another possible mechanism to explain the cross-sectional and 
longitudinal associations observed between OSA and microvascular complications and endothelial 
dysfunction observed in patients with type 2 diabetes (Altaf et al., 2015;Tahrani et al., 2012a;Tahrani 
et al., 2013a;Tahrani et al., 2013b). PARP inhibition has been shown to alleviate oxidative stress and 
reverse DPN and neuropathy in diabetic rodents (Drel et al., 2010;Drel et al., 2011;Lupachyk et al., 
2011). Intermittent hypoxia has been shown to result in oxidative stress and PARP activation in in-
vitro non-diabetic rodents (Chiu et al., 2012). 
We also found that OSA is independently associated with DFU in patients with Type 2 diabetes. This 
association was independent of important risk factors such as PVD, BMI, age, diabetes duration and 
HbA1c. Considering that OSA is associated with DPN, endothelial dysfunction, oxidative stress, 
nitrosative stress, lower IENFD and PARP activation, this association between OSA and DFU may not 
be surprising. A recent in-vitro study showed that the serum from patients with OSA and the 
metabolic syndrome resulted in impaired endothelial wound healing compared to healthy controls 
(Briançon-Marjollet et al., 2014). However, a small study of 25 patients with OSA showed no 
evidence of impaired wound healing following partial foot amputation (Andrews et al., ). A recently 
published case series (n=3) suggested that CPAP treatment aided DFU healing in 2 patients with 
undiagnosed OSA and DFU (Vas et al., 2015). The impact of OSA on DFU and wound healing in 
patients with type 2 diabetes requires further prospective and interventional studies. 
This study has several limitations, most importantly its cross-sectional design where causality cannot 
be proven. Although several reasons might explain how OSA might result in lower IENFD, PARP 
activation and DFU, it is plausible for neuropathy to result or worsen OSA by its impact on upper 
airway function and the ventilatory drive. Hence, it is possible that the relationship could be bi-
directional. The rather small sample size is another limiting factor but not many patients were willing 
to have skin biopsy which is a mini-invasive procedure, but 52 patients is comparable (and even 
more) than many other studies of skin biopsies in patients with Type 2 diabetes.  
Our study also has strengths. The population of the study were well characterized and this is the first 
report to examine the relationship between OSA and IENFD, PARP and DFU in patients with type 2 
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diabetes. This is also the first report to show a relationship between OSA and IENFD and PARP 
activation in humans.  
In summary, OSA was associated with lower IENFD, PARP activation and DFU in patients with Type 2 
diabetes. PARP activation could be one of the mechanisms relating OSA to microvascular dysfunction 
and complications in patients with Type 2 diabetes. Whether PARP inhibition would be beneficial 
requires further studies. The impact of OSA on IENFD, PARP and DFU requires further prospective 
studies. Whether continuous positive airway pressure treatment can improve IENFD, inhibit PARP 
and/or reduce the incidence/improve the healing of DFU requires interventional studies. 
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Table 1: The characteristics of patients who had skin biopsies in relation to OSA status. BP: blood 
pressure; BMI: body mass index; PVD: peripheral vascular disease; eGFR: estimated glomerular 
filtration rate, EDS: excessive daytime sleepiness (i.e. Epworth sleepiness score ≥ 11). 
  No OSA  
(n = 9) 
Mild OSA  
(n = 24) 
Moderate to 
severe OSA  
(n = 19) 
p 
Age, yr 59.57 (8.86) 59.66 (12.49) 62.62 (8.42) 0.385 
Male 4 (44.4%) 19 (79.2%) 25 (78.9%) 0.104 
White 6 (66.7%) 18 (75%) 17 (89.5%) 0.317 
Diabetes duration, yr 12 (8 – 14) 13 (10 – 18.5) 15 (7 – 23) 0.437 
Hba1c, % 7.98 (1.65) 8.5 (1.26) 8.01 (1.29) 0.618 
Total cholesterol, mmol/L 3.77 (0.73) 3.79 (0.79) 3.89 (1.15) 0.25 
HDL, mmol/L 1.23 (0.35) 1.13 (0.38) 1.16 (0.33) 0.995 
LDL, mmol/L 1.74 (0.83) 1.86 (0.72) 1.77 (0.90) 0.673 
Triglycerides, mmol/L 1.71 ( 0.95) 1.74 (0.86) 1.92 (0.86) 0.878 
Systolic BP, mmHg 130.2 (18.17) 135.5 (14.33) 132.18 (23.02) 0.328 
Diastolic BP, mmHg 81.66 (8.34) 79.77 (10.61) 76.1 (7.30) 0.667 
Epworth Sleepiness Score 10.67 (4.72) 8.13 (4.87) 10.72 (4.50) 0.160 
EDS 5 (55.6%) 7 (29.2%) 10 (52.6%) 0.204 
BMI, kg/m2  35.61 (12.89) 34.41 (6.01) 37.6 (8.76) 0.145 
Waist/hip ratio 0.96 (0.08) 1.00 (0.04) 1.01 (0.06) 0.146 
MNSIe score  0.5 (0 – 1.5) 3 (2 – 4.75) 4 (3.5 – 5) <0.05 
e-GFR, ml/min/1.73m2  91.75 (28.89) 82.41 (29.29) 74.68 (26.01) 0.974 
Alcohol 5 (55.6%) 15 (62.5%) 9 (47.4%) 0.611 
Smoking (current or ex) 5 (55.6%) 11 (45.8%) 8 (42.1%) 0.800 
Insulin 6 (66.7%) 14 (58.3%) 11 (57.9%) 0.893 
GLP-1 1 (11.1%) 1 (4.2%) 2 (10.5%) 0.676 
Oral antidiabetic treatment 8 (88.9%) 24 (100%) 16 (84.2%) 0.142 
Antihypertensive agents 7 (77.8%) 20 (83.3%) 19 (100%) 0.129 
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Table 2: Participant characteristics in relation to SDB status. Data presented as median (IQR) or mean 
(SD). Categorical variables presented as number (% of SDB status).GFR: Glomerular Filtration Rate, 
TIA: Transient Ischaemic Attack, PVD: Peripheral Vascular Disease, EDS: Excessive Daytime Sleepiess. 
Analysis performed using the Chi-square test for categorical variables, the independent t test for 
normally distributed variables and the Mann-Whitney U test for non-normally distributed variables. 
Adapted with permission from (2). 
 OSA- (n=83) OSA+ (n=151) P value 
Male 34 (41%) 101 (67%) < 0.001 
Caucasians 32 (39%) 97 (64%) <0.001 
Age (years) 54.7 (11.9) 58.5 (11.3) 0.02 
Diabetes Duration (years) 9 (5-15) 11 (7-17) 0.02 
Body Mass Index (kg/m2) 30.2 (27.3-35.0) 34.4 (30.9-39.5) < 0.001 
Waist circumference (cm) 105.5 (96.0-115.0) 116.0 (107.5-125.5) < 0.001 
Hip (cm) 106.0 (98.0-117.0) 114.0 (105.0-125.0) < 0.001 
Waist hip ratio 0.97 (0.93-1.02) 1.01 (0.96-1.05) 0.002 
Neck circumference (cm) 38.0 (36.5-41.3) 43.0 (39.0-46.0) < 0.001 
Height (cm) 163.5 (8.3) 167.8 (10.0) 0.001 
Systolic blood pressure (mmHg) 125.5 (115.0-135.5.0) 130.0 (123.5-140.0) 0.002 
Diastolic blood pressure (mmHg) 78.50 (71.0-85.00) 78.00 (71.00-84.50) 0.88 
HbA1c (%) 7.7 (7.0-8.7) 8.3 (7.3-9.3) 0.05 
Total cholesterol (mmol/L) 3.7 (3.4-4.5) 3.7 (3.3-4.3) 0.57 
Triglycerides (mmol/L) 1.5 (1.0-2.1) 1.8 (1.3-2.5) 0.03 
HDL (mmol/L) 1.2 (0.9-1.4) 1.1 (0.9-1.2) 0.02 
Estimated GFR (ml/min/1.73 m2) 92.92 (25.16) 82.41 (26.41) 0.003 
Lipid lowering treatment 9 (100%) 20 (83.3%) 19 (100%) 0.080 
PVD 0 (0.0%) 1 (4.2%) 3 (15.8%) 0.232 
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TSH 1.6 (1.0-2.2) 1.7 (1.2-2.4) 0.32 
Epworth sleepiness score  5.0 (2.0-12.0) 8.0 (4.0-13.0) 0.003 
EDS 30.1% (n=25) 39.1% (n=59) 0.172 
Smoking (current or ex-smoker) 32 (39%) 62 (41%) 0.71 
Alcohol (drinks alcohol) 12 (15%) 12 (35%) 0.001 
Oral anti-diabetes treatment 81 (98%) 137 (91%) 0.05 
Insulin 34 (41%) 91 (60%) 0.005 
Insulin dose (units) 61 (35-88) 80 (56-118) 0.007 
ACE inhibitors  40 (48%) 69 (46%) 0.71 
Anti-hypertensive agents 61 (74%) 129 (85%) 0.03 
Lipid lowering treatment 71 (86%) 125 (83%) 0.58 
Stroke or TIA 60 (7%) 18 (12%) 0.28 
Ischemic heart disease 14 (17%) 33 (22%) 0.40 
PVD 1 (1%) 10 (7%) 0.06 
Albuminuria 20 (24%) 65 (43%) 0.007 
Sight threatening retinopathy 17 (21%) 72 (48%) < 0.001 
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Figure 1: The study diagram 
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Figure 2 - The relationship between obstructive sleep apnoea and Intra epidermal nerve fibre density 
(IENFD). 
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Figure 3: PAR immunostaining from A) patient with AHI of 1.6, B) patient with AHI 31.2. Black arrow: 
non PAR stained nuclei (purple), Red arrow: PAR stained nuclei (brown) 
A: 
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Highlights  
1. OSA is associated with lower IENFD in patients with Type 2 diabetes (T2D) 
2. OSA is associated with small as well as large fibre dysfunction in patients with T2D. 
3. OSA is associated with PARP activation in patients with T2D 
4.  OSA is associated with foot ulceration in patients with T2D. 
5. The impact of CPAP on IENFD and foot ulceration in T2D need to be examined. 
